 Last month, management guided Zilretta revenue to grow 50 to 120-130 million. Huge runway with under 5 market penetration into osteoarthritis knee pain indication. Despite growing revenue nearly 20 last year during the pandemic and guiding to 50 this year, shares trade at a 52-week low and under 4x revenue multiple. 